Octreotide(Synonyms: 奥曲肽 SMS 201-995)

Octreotide;(Synonyms: 奥曲肽; SMS 201-995) 纯度: 98.84%

Octreotide 是一种生长抑素类似物,能够与 somatostatin 受体结合,主要有 2,3,5 亚型,可增强 Gi 活性,降低胞内 cAMP 的产生。

Octreotideamp;;(Synonyms: 奥曲肽; SMS 201-995)

Octreotide Chemical Structure

CAS No. : 83150-76-9

规格 价格 是否有货 数量
1 mg ¥500 In-stock
5 mg ¥1200 In-stock
10 mg ¥2000 In-stock
25 mg ¥4000 In-stock
50 mg ; 询价 ;
100 mg ; 询价 ;

* Please select Quantity before adding items.

Octreotide 相关产品

bull;相关化合物库:

  • Drug Repurposing Compound Library Plus
  • FDA-Approved Drug Library Plus
  • Bioactive Compound Library Plus
  • Peptidomimetic Library
  • Peptide Library

生物活性

Octreotide is a somatostatin analog that binds to the somatostatin receptor, mainly subtypes 2, 3, and 5, increases Gi activity, and reduces intracellular cAMP production.

体外研究
(In Vitro)

Octreotide reverses the PA-induced alterations in Akt and GSK3β phosphorylation and expression of GS mRNA in HepG2 cells[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究
(In Vivo)

Octreotide significantly lowers the plasma glucose levels in the obese rats of the HFD group. Octreotide intervention significantly decreases the serum insulin concentration; however, there is no marked reduction in serum TG, TC, FFA, ALT and AST levels. Octreotide significantly inhibits the HOMA index. Octreotide decreases ipGTT and ipITT AUCs, but not significantly. Octreotide improves fat degeneration in rats with HFD-induced obesity and lipid droplet accumulation in PA-treated HepG2 cells. Octreotide promotes the phosphorylation of Akt and GSK3β and the expression of GS mRNA in rats with HFD-induced obesity[1]. Octreotide reduces body weight and wet kidney weight compared with the vehicle-treated (CONT) group. PAS and Octreotide/PAS treatment decrease cAMP levels, but Octreotide alone does not in PCK rats. In the Octreotide/PAS group, there are a significantly fewer pS6-positive cells than in the PAS alone group[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

分子量

1019.24

Formula

C49H66N10O10S2

CAS 号

83150-76-9

Sequence

Phe-Cys-Phe-Trp-Lys-Thr-Cys-Thr (Disulfide bridge: Cys2-Cys7)

Sequence Shortening

FCFWKTCT (Disulfide bridge: Cys2-Cys7)

中文名称

奥曲肽

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Protect from light

Powder -80deg;C 2 years
-20deg;C 1 year

*该产品在溶液状态不稳定,建议您现用现配,即刻使用。

溶解性数据
In Vitro:;

H2O : 100 mg/mL (98.11 mM; Need ultrasonic)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 0.9811 mL 4.9056 mL 9.8112 mL
5 mM 0.1962 mL 0.9811 mL 1.9622 mL
10 mM 0.0981 mL 0.4906 mL 0.9811 mL

*

请根据产品在不同溶剂中的溶解度,选择合适的溶剂配制储备液;该产品在溶液状态不稳定,建议您现用现配,即刻使用

参考文献
  • [1]. Wang XX, et al. Effects of octreotide on hepatic glycogenesis in rats with high fat diet?induced obesity. Mol Med Rep. 2017 Jul;16(1):109-118

    [2]. Kugita M, et al. Beneficial effect of combined treatment with octreotide and pasireotide in PCK rats, an orthologous model of human autosomal recessive polycystic kidney disease. PLoS One. 2017 May 18;12(5):e0177934.

Animal Administration
[2]

AMale PCK rats (n = 24) are assigned randomly to 1 of 4 groups (n = 6 per group): treatment by subcutaneous injection every 4 weeks treatment with 8 mg/kg Octreotide-LAR alone, 8 mg/kg PAS-LAR alone, co-application of 8 mg/kg Octreotide and 8 mg/kg PAS, or vehicle (microparticles liquid; CONT) from 4 to 16 weeks of age. The vehicle contains copolymer microparticles with polylactic-co-glycolic acid (PLGA). In 4- and 15-week-old conscious rats, heart rate (HR), diastolic blood pressure (DBP), and systolic blood pressure (SBP) are determined using a tail-cuff sphygmomanometer. Twenty-four-hour urine volume and food consumption are measured using metabolic cages after 15.5 weeks of age. After body weight measurement, the animals are anesthetized with sodium pentobarbital at 16 weeks of age, and the kidneys and liver are removed rapidly, causing lethal exsanguination. Total wet kidney weight and wet liver weight are measured, and blood samples are collected for measurements of serum urea nitrogen (SUN), aspartate amino transferase (AST), alanine aminotransferase (ALT), insulin-like growth factor-1 (IGF-1), glucose, insulin, glucagon, and cortisol.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

参考文献
  • [1]. Wang XX, et al. Effects of octreotide on hepatic glycogenesis in rats with high fat diet?induced obesity. Mol Med Rep. 2017 Jul;16(1):109-118

    [2]. Kugita M, et al. Beneficial effect of combined treatment with octreotide and pasireotide in PCK rats, an orthologous model of human autosomal recessive polycystic kidney disease. PLoS One. 2017 May 18;12(5):e0177934.

发表回复